Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 26

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 26
---
 a third party against a charge of infringement can involve lengthy and costly        
 legal actions, and there can be no guarantee of a successful outcome. Biotechnology companies        
 comparable to us in size and financial position have discontinued business after losing infringement 
 battles. If we or our partners were prevented from using or selling our human-use equipment,         
 then our business would be materially adversely affected.                                            |

| ● | Freedom                                                                                    
 to Operate Issues. The competitive nature of our field of business and the fact that       
 others have sought patent protection for technologies similar to ours make these potential 
 issues significant.                                                                        |

In addition to patents, we also rely on trade secrets and proprietary know-how. We try to protect this information with appropriate confidentiality and inventions agreements with our employees, scientific advisors, consultants, and collaborators. We cannot be sure that these agreements will not be breached, that we will be able to protect ourselves if they are breached, or that our trade secrets will not otherwise become known or be independently discovered by competitors. If any of these events occur, then we face the potential of losing control over valuable company information, which could negatively affect our competitive position.

We may be subject to legal claims against us or claims by us which could have a significant impact on our resulting financial performance.

At any given time, we may be subject to litigation, the disposition of which may have an adverse effect upon our business, financial condition, or results of operation. Such claims include but are not limited to and may arise from product liability and related claims in the event that any of the products that we sell is faulty or contain defects in materials or design. We may be subject to infringement claims from our products. In addition, we may be subject to claims by our lenders, claims for rent, and claims from our vendors on our accounts payable; and although we have been able to obtain understandings with the foregoing and have informal forbearance agreements from those parties, one or more of them may elect to commence collection proceedings which could result in judgments against us and have a significant negative impact on our operations.

<div align='center'>15</div>

Risks Relating to Operations in Israel

Conditions in Israel, including the ongoing war between Israel and Hamas and other Iranian proxies, and other conflicts in the region, may adversely affect our operations and limit our ability to develop and market our product candidates.

A significant portion of our R&D operations is based in Israel. Recent escalations in regional conflicts have disrupted business activities and may continue to do so. We have developed contingency plans, including